Neurocrine reports Q2 non-GAAP EPS $1.25, consensus 78c

Reports Q2 revenue $452.7M, consensus $447.31M. “INGREZZA’s performance reflects the significant benefit the medicine is providing to patients with tardive dyskinesia enabling us to raise guidance once again,” said Kevin Gorman, CEO. “Operationally, we are set up well in the second half of 2023 with growing INGREZZA sales, a PDUFA for valbenazine to treat chorea associated with Huntington’s disease, and meaningful progress with our muscarinic programs. Importantly, we remain on-track for four pipeline read-outs in the fourth quarter, including the Phase 3 studies of crinecerfont for the treatment of pediatric and adult congenital adrenal hyperplasia.”